Description

Senior executive, consultant, and entrepreneur with 25+ years of experience leading business transformation, digital strategy, enterprise data, analytics, AI, and healthcare innovation initiatives across healthcare, life sciences, technology, and multinational organisations.

Former senior leader at Novartis, PwC, IBM, and Sapient with extensive experience designing and delivering large-scale transformation programmes, operating model redesign, operational improvement, performance measurement, digital products, data strategy, business intelligence, and advanced analytics capabilities. Currently CEO of an Imperial College London spinout developing AI- and sensor-based digital biomarkers for neurological and rare diseases.

Industry field of expertise

Languages

English
Native or bilingual

Workplace preferences

Can work on-site

London (up to 50km)

Independent
Health Innovation Advisor & Independent Consultant
CONSULTING AND AUDITS
January 2019 - Today (7 years and 6 months)
Advisor to healthcare organisations, startups, researchers, and innovation programmes on digital health, AI, data strategy, and transformation. Startup due diligence and judge. European Health Data Space Working Group. Frequent panelist and speaker.
Ethomix (Imperial College Spinout)
CEO
January 2023 - Today (3 years and 6 months)
Leading commercialisation of AI- and sensor-enabled digital biomarkers for neurological and rare diseases. Engaging with FDA, MHRA and EMA on data qualification for Clinical Trials. Stakeholder engagement across clinical, life science, technology and academic systems internationally.
Advisor to healthcare organisations, startups, researchers, and innovation programmes on digital health, AI, data strategy, and transformation. Startup due diligence and judge. European Health Data Space Working Group. Frequent panelist and speaker.
Novartis
Director, Commercial IT Data Products
January 2015 - January 2019 (4 years)
Led global data, analytics, and commercial technology products supporting operations across 180 countries. Commercial and Real World Evidence. M&A carve out for Alcon business. Operation and performance improvement in Commercial Divison.